Allylestrenol


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Threatened miscarriage 5 mg tid for 5-7 days, treatment may be prolonged if necessary. Gradually reduce dosage if symptoms disappear. Recurrent miscarriage 5-10 mg/day as soon as pregnancy is confirmed. Continue treatment for at least 1 month after the critical period. Threatened premature labour Individualise dosage. Max: 40mg/day.
Dosage Details
Oral
Threatened miscarriage
Adult: 5 mg tid for 5-7 days, treatment may be prolonged if necessary. Gradually reduce dosage if symptoms disappear.

Oral
Recurrent miscarriage
Adult: 5-10 mg daily as soon as pregnancy is confirmed. Continue treatment for at least 1 month after the critical period.

Oral
Premature labour
Adult: For threatened premature labour: Individualise dosage. Max: 40mg daily.
Hepatic Impairment
Contraindicated.
Administration
May be taken with or without food. May be taken w/ meals if GI upset occurs.
Contraindications
Hypersensitivity. Hepatic impairment.
Special Precautions
Patient with diabetes. Pregnancy.
Adverse Reactions
Significant: Visual disturbances, proptosis or diplopia, vascular retinal ulcer; migraine.
Gastrointestinal disorders: Nausea, vomiting.
Action
Description: Allylestrenol is a synthetic progestogen structurally related to progesterone. It exhibits trophoblastic, placentotrophic, and β2-adrenergic activity with no androgenic action. Allylestrenol stimulates the hormonal effects of existing syncytiotrophoblast which are necessary for progesterone production. The pregnancy-maintaining effect is due to the stimulation of the placental function, and the stimulation of β2-adrenergic receptors prevents uterine contractility.
Chemical Structure

Click on icon to see table/diagram/image
ATC Classification
G03DC01 - allylestrenol ; Belongs to the class of estren derivative progestogens used in progestogenic hormone preparations.
Disclaimer: This information is independently developed by MIMS based on Allylestrenol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in